Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

NCT04887948 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

570

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Disease
COVID-19
SARS-CoV-2 Infection

Interventions

BIOLOGICAL: 20-valent pneumococcal conjugate vaccine (20vPnC)
BIOLOGICAL: BNT162b2
OTHER: Saline

Sponsor

Pfizer